Avacopan

Description: Avacopan (CCX168) is an orally administered small-molecule C5aR ( IC50 : 0.1 nM.)antagonist that blocks the effects of C5a and prevents the development of GN induced by anti-myeloperoxidase antibodies in a murine model of AAV. Target: Complement System. Smiles: C(=O)(N1[C@H]([C@@H](C(NC2=CC(C(F)(F)F)=C(C)C=C2)=O)CCC1)C3=CC=C(NC4CCCC4)C=C3)C5=C(C)C=CC=C5F. References: Bekker P, et al. Characterization of Pharmacologic and Pharmacokinetic Properties of CCX168, a Potent and Selective Orally Administered Complement 5a Receptor Inhibitor, Based on Preclinical Evaluation and Randomized Phase 1 Clinical Study. PLoS One. 2016 Oct 21,11(10):e0164646.